We are preparing the requested document. Please wait, this may take a while...!
|Antigen||Vascular Endothelial Growth Factor B (VEGFB) Antibodies|
|Reactivity||Human, Mouse (Murine), Rat (Rattus) Alternatives|
|Conjugate||This VEGFB antibody is un-conjugated Alternatives|
Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
|Supplier||Log in to see|
Product Details anti-VEGFB AntibodyTarget Details VEGFB Application Details Handling Images
|Purification||Purified by Protein A.|
|Immunogen||KLH conjugated synthetic peptide derived from human VEGFB|
Target Details VEGFBProduct Details anti-VEGFB Antibody Application Details Handling Images back to top
|Alternative Name||VEGFB (VEGFB Antibody Abstract)|
The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described and include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factors (VEGFs). The VEGF protein family is comprised of VEGF, VEGF-B, VEGF-C and VEGF-D, all of which may exhibit angiogenic function in vivo. VEGF-B, which exists as two alternatively spliced isoforms known as VEGF-B167 and VEGF-B186, is abundantly expressed in heart and skeletal muscle and is frequently co-expressed with VEGF. VEGF-C binds to and specifically activates Flt-4 and Flk-1.
Synonyms: Vascular endothelial growth factor B, VEGF B, VEGFB, VEGF-B, VEGF related factor, VEGFL, Vrf, vascular endothelial growth factor B isoform VEGFB-167 precursor, VEGFB_HUMAN.
|Pathways||RTK Signaling, Signaling Events mediated by VEGFR1 and VEGFR2, VEGFR1 Specific Signals|
Application DetailsProduct Details anti-VEGFB Antibody Target Details VEGFB Handling Images back to top
|Restrictions||For Research Use only|
HandlingProduct Details anti-VEGFB Antibody Target Details VEGFB Application Details Images back to top
|Buffer||Aqueous buffered solution containing 1 % BSA, 50 % glycerol and 0.09 % sodium azide.|
|Precaution of Use||This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.|
|Storage Comment||Store at -20°C|
|Expiry Date||12 months|
ImagesProduct Details anti-VEGFB Antibody Target Details VEGFB Application Details Handling back to top